31 results on '"Borg, Brian"'
Search Results
2. Efficacy and Safety of Sofosbuvir/Velpatasvir plus Ribavirin in Patients with Hepatitis C Virus-Related Decompensated Cirrhosis
- Author
-
Flamm, Steven, primary, Lawitz, Eric, additional, Borg, Brian, additional, Charlton, Michael, additional, Landis, Charles, additional, Reddy, K. Rajender, additional, Shiffman, Mitchell, additional, Alsina, Angel, additional, Chang, Charissa, additional, Ravendhran, Natarajan, additional, Hernandez, Candido, additional, Hézode, Christophe, additional, Scherbakovsky, Stacey, additional, Mercier, Renee-Claude, additional, and Samuel, Didier, additional
- Published
- 2023
- Full Text
- View/download PDF
3. Open‐label, clinical trial extension: Two‐year safety and efficacy results of seladelpar in patients with primary biliary cholangitis.
- Author
-
Mayo, Marlyn J., Vierling, John M., Bowlus, Christopher L., Levy, Cynthia, Hirschfield, Gideon M., Neff, Guy W., Galambos, Michael R., Gordon, Stuart C., Borg, Brian B., Harrison, Stephen A., Thuluvath, Paul J., Goel, Aparna, Shiffman, Mitchell L., Swain, Mark G., Jones, David E. J., Trivedi, Palak, Kremer, Andreas E., Aspinall, Richard J., Sheridan, David A., and Dörffel, Yvonne
- Subjects
CHOLANGITIS ,CLINICAL trials ,ADVERSE health care events ,NON-alcoholic fatty liver disease ,BIOMARKERS - Abstract
Summary: Background: Seladelpar is a potent and selective peroxisome proliferator‐activated receptor‐δ agonist that targets multiple cell types involved in primary biliary cholangitis (PBC), leading to anti‐cholestatic, anti‐inflammatory and anti‐pruritic effects. Aims: To evaluate the long‐term safety and efficacy of seladelpar in patients with PBC. Methods: In an open‐label, international, long‐term extension study, patients with PBC completing seladelpar lead‐in studies continued treatment. Seladelpar was taken orally once daily at doses of 5 or 10 mg with dose adjustment permitted for safety or tolerability. The primary analysis was for safety and the secondary efficacy analysis examined biochemical markers of cholestasis and liver injury. The study was terminated early due to the unexpected histological findings in a concurrent study for non‐alcoholic steatohepatitis, which were subsequently found to predate treatment. Safety and efficacy data were analysed through 2 years. Results: There were no serious treatment‐related adverse events observed among 106 patients treated with seladelpar for up to 2 years. There were four discontinuations for safety, one possibly related to seladelpar. Among 53 patients who completed 2 years of seladelpar, response rates increased from years 1 to 2 for the composite endpoint (alkaline phosphatase [ALP] <1.67 × ULN, ≥15% decrease in ALP, and total bilirubin ≤ULN) and ALP normalisation from 66% to 79% and from 26% to 42%, respectively. In those with elevated bilirubin at baseline, 43% achieved normalisation at year 2. Conclusions: Seladelpar was safe, and markedly improved biochemical markers of cholestasis and liver injury in patients with PBC. These effects were maintained or improved throughout the second year. Clinicaltrials.gov: NCT03301506; Clinicaltrialsregister.eu: 2017‐003910‐16. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
4. Rosai-Dorfman Disease Masquerading as Cholangiocarcinoma
- Author
-
Teymoorian, Arian, Earl, Truman M., and Borg, Brian B.
- Published
- 2017
- Full Text
- View/download PDF
5. Su1348: EFFICACY, SAFETY, AND TOLERABILITY OF SELADELPAR IN PATIENTS WITH COMPENSATED LIVER CIRRHOSIS DUE TO PRIMARY BILIARY CHOLANGITIS (PBC); A POOLED ANALYSIS OF PHASE 2 AND PHASE 3 STUDIES
- Author
-
Gordon, Stuart C., primary, Trivedi, Palak, additional, Bowlus, Christopher L., additional, Galambos, Michael, additional, Goel, Aparna, additional, Gulamhusein, Aliya, additional, Levy, Cynthia, additional, Neff, Guy, additional, Stanca, Carmen M., additional, Thorburn, Douglas, additional, Bacon, Bruce R., additional, Borg, Brian B., additional, Doerffel, Yvonne, additional, Forman, Lisa, additional, Freilich, Bradley, additional, Gheorghe, Liliana, additional, Gonzalez-Huezo, Maria Sarai, additional, Harrison, Stephen A., additional, Huang, Jonathan C., additional, Jeong, Sook-Hayng, additional, Kim, Seung-Up, additional, Lake, John, additional, Odin, Joseph, additional, Tak, Won Young, additional, Tobias, Hillel, additional, Vierling, John M., additional, Yang, Ke, additional, Steinberg, Alexandra, additional, Choi, Yun-Jung, additional, Mcwherter, Charles A., additional, and Mayo, Marlyn J., additional
- Published
- 2022
- Full Text
- View/download PDF
6. Immunization with Hepatitis C Virus-Like Particles Results in Control of Hepatitis C Virus Infection in Chimpanzees
- Author
-
Elmowalid, Gamal A., Qiao, Ming, Jeong, Sook-Hyang, Borg, Brian B., Baumert, Thomas F., Sapp, Ronda K., Hu, Zongyi, Murthy, Krishna, and Liang, T. Jake
- Published
- 2007
- Full Text
- View/download PDF
7. A Functional SNP of Interferon-γ Gene Is Important for Interferon-α-Induced and Spontaneous Recovery from Hepatitis C Virus Infection
- Author
-
Huang, Ying, Yang, Huiying, Borg, Brian B., Su, Xiaowen, Rhodes, Shannon L., Yang, Kai, Tong, Xiaomei, Tang, George, Howell, Charles D., Rosen, Hugo R., Thio, Chloe L., Thomas, David L., Alter, Harvey J., Sapp, Ronda K., and Liang, T. Jake
- Published
- 2007
- Full Text
- View/download PDF
8. Reactivation of Hepatitis B With Reappearance of Hepatitis B Surface Antigen After Chemotherapy and Immunosuppression
- Author
-
Palmore, Tara N., Shah, Neeral L., Loomba, Rohit, Borg, Brian B., Lopatin, Uri, Feld, Jordan J., Khokhar, Farooq, Lutchman, Glen, Kleiner, David E., Young, Neal S., Childs, Richard, Barrett, A. John, Liang, T. Jake, Hoofnagle, Jay H., and Heller, Theo
- Published
- 2009
- Full Text
- View/download PDF
9. Impact of Obesity on Bowel Preparation for Colonoscopy
- Author
-
Borg, Brian B., Gupta, Nitin K., Zuckerman, Gary R., Banerjee, Bhaskar, and Gyawali, C. Prakash
- Published
- 2009
- Full Text
- View/download PDF
10. A functional SNP of interferon-[gamma], gene is important for interferon-[alpha]-induced and spontaneous recovery from hepatitis C virus infection
- Author
-
Huang, Ying, Yang, Huiying, Borg, Brian B., Su, Xiaowen, Rhodes, Shannon L., Yang, Kai, Tong, Xiaomei, Tang, George, Howell, Charles D., Rosen, Hugo R., Thio, Chloe L., Thomas, David L., Alter, Harvey J., Sapp, Ronda K., and Liang, T. Jake
- Subjects
Hepatitis C virus -- Drug therapy ,Hepatitis C virus -- Research ,Hepatitis C virus -- Genetic aspects ,Genetic polymorphisms -- Research ,Cytokines -- Genetic aspects ,Cytokines -- Research ,Science and technology - Abstract
Cytokine polymorphisms are associated with disease outcome and interferon (IFN) treatment response in hepatitis C virus (HCV) infection. We genotyped eight SNPs spanning the entire IFN-[gamma] gene in two cohorts and assessed the association between those polymorphisms and treatment response or spontaneous viral clearance. The first cohort was composed of 284 chronically HCV-infected patients who had received IFN-[alpha]-based therapy and the second was 251 i.v. drug users who had either spontaneously cleared HCV or become chronically infected. A SNP variant located in the proximal IFN-[gamma], promoter region next to the binding motif of heat shock transcription factor (HSF), -764G, was significantly associated with sustained virological response [P = 0.04, odds ratio (OR) = 3.51 (confidence interval 1.0-12.5)]. The association was independently significant in multiple logistic regression (P = 0.04) along with race, viral titer, and genotype. This variant was also significantly associated with spontaneous recovery [P = 0.04, OR = 3.51 (1.0-12.5)] in the second cohort. Functional analyses show that the G allele confers a two- to three-fold higher promoter activity and stronger binding affinity to HSF1 than the C allele. Our study suggests that the IFN-[gamma] promoter SNP -764G/C is functionally important in determining viral clearance and treatment response in HCV-infected patients and may be used as a genetic marker to predict sustained virological response in HCV-infected patients. genetics | human study | cytokine | viral clearance | antiviral treatment
- Published
- 2007
11. Immune Response to Extracellular Matrix Collagen in Chronic Hepatitis C–Induced Liver Fibrosis
- Author
-
Borg, Brian B., Seetharam, Anil, Subramanian, Vijay, Basha, Haseeb Ilias, Lisker-Melman, Mauricio, Korenblat, Kevin, Anderson, Christopher D., Shenoy, Surendra, Chapman, William C., Crippin, Jeffrey S., and Mohanakumar, Thalachallour
- Published
- 2011
- Full Text
- View/download PDF
12. 686 EFFECTS ON PRURITUS AND SLEEP DISTURBANCE IN PATIENTS WITH PRIMARY BILIARY CHOLANGITIS (PBC) AFTER 1 YEAR OF TREATMENT WITH SELADELPAR, A PEROXISOME PROLIFERATOR-ACTIVATED RECEPTOR DELTA AGONIST: RESULTS OF AN OPEN-LABEL PHASE 2 STUDY
- Author
-
Kremer, Andreas E., primary, Mayo, Marlyn J., additional, Bowlus, Christopher L., additional, Neff, Guy, additional, Swain, Mark G., additional, Galambos, Michael, additional, Goel, Aparna, additional, Trivedi, Palak, additional, Hirschfield, Gideon, additional, Aspinall, Richard, additional, Gordon, Stuart C., additional, Borg, Brian B., additional, Harrison, Stephen, additional, Thuluvath, Paul, additional, Jones, David E., additional, Doerffel, Yvonne, additional, Levy, Cynthia, additional, Stanca, Carmen, additional, Sheridan, David, additional, Vierling, John M., additional, Shiffman, Mitchell L., additional, Odin, Joseph, additional, Bacon, Bruce, additional, Hassanein, Tarek, additional, Thorburn, Douglas, additional, Berg, Christoph, additional, Bernstein, David, additional, Gulamhusein, Aliya, additional, Landis, Charles, additional, Peyton, Adam, additional, Corless, Lynsey, additional, Buggisch, Peter, additional, Wörns, Marcus-Alexander, additional, Bergheanu, Sandrin, additional, Varga, Monika, additional, Li, Yu, additional, Yang, Ke, additional, Dickinson, Klara, additional, Boudes, Pol, additional, McWherter, Charles A., additional, Steinberg, Alexandra, additional, and Choi, Yun-Jung, additional
- Published
- 2020
- Full Text
- View/download PDF
13. Effects of Belapectin, an Inhibitor of Galectin-3, in Patients With Nonalcoholic Steatohepatitis With Cirrhosis and Portal Hypertension
- Author
-
Chalasani, Naga, primary, Abdelmalek, Manal F., additional, Garcia-Tsao, Guadalupe, additional, Vuppalanchi, Raj, additional, Alkhouri, Naim, additional, Rinella, Mary, additional, Noureddin, Mazen, additional, Pyko, Maxmillan, additional, Shiffman, Mitchell, additional, Sanyal, Arun, additional, Allgood, Adam, additional, Shlevin, Harold, additional, Horton, Rex, additional, Zomer, Eliezer, additional, Irish, William, additional, Goodman, Zachary, additional, Harrison, Stephen A., additional, Traber, Peter G., additional, Abdelmalek, Manal, additional, Balart, Luis, additional, Borg, Brian, additional, Chalasani, Naga, additional, Charlton, Michael, additional, Conjeevaram, Hari, additional, Fuchs, Michael, additional, Ghalib, Reem, additional, Gholam, Pierre, additional, Halegoua-De Marzio, Dina, additional, Harrison, Stephen, additional, Jue, Christopher, additional, Kemmer, Nyingi, additional, Kowdley, Kris, additional, Lai, Michelle, additional, Lawitz, Eric, additional, Loomba, Rohit, additional, Paredes, Angelo, additional, Rockey, Don, additional, Rodriguez, Miguel, additional, Rubin, Raymond, additional, Ryan, Michael, additional, Scanga, Andrew, additional, Sepe, Thomas, additional, Tetri, Brent, additional, Thuluvath, Paul, additional, Torres, Dawn, additional, Vierling, John, additional, Wattacheril, Julia, additional, Weiland, Amanda, additional, and Zogg, Donald, additional
- Published
- 2020
- Full Text
- View/download PDF
14. 953 – High Efficacy and Improvement in Cpt Class with Sofosbuvir/Velpatasvir Plus Ribavirin for 12 Weeks in Patients with Cpt C Decompensated Cirrhosis
- Author
-
Flamm, Steven L., primary, Lawitz, Eric, additional, Borg, Brian, additional, Charlton, Michael, additional, Landis, Charles, additional, Reddy, K. Rajender, additional, Shiffman, Mitchell L., additional, Samuel, Didier, additional, Alsina, Angel, additional, Chang, Charissa Y., additional, Ravendhran, Natarajan, additional, Zhang, Gulan, additional, Cheinquer, Nelson, additional, Moon, Scott, additional, Spellman, James, additional, Stamm, Luisa, additional, Gaggar, Anuj, additional, and Hezode, Christophe, additional
- Published
- 2019
- Full Text
- View/download PDF
15. Mo1473 – Seladelpar for the Treatment of Primary Biliary Cholangitis: Experience with 26 Cirrhotic Patients
- Author
-
Mayo, Marlyn J., primary, Bowlus, Christopher L., additional, Galambos, Michael, additional, Neff, Guy, additional, Trivedi, Palak, additional, Goel, Aparna, additional, Odin, Joseph, additional, Bacon, Bruce R., additional, Borg, Brian B., additional, Gordon, Stuart C., additional, Gulamhusein, Aliya, additional, Harrison, Stephen, additional, Levy, Cynthia, additional, stanca, carmen, additional, Vierling, John M., additional, Steinberg, Alexandra, additional, Varga, Monika, additional, Nguyen, Jaidyn, additional, Bergheanu, Sandrin, additional, Choi, Yun-Jung, additional, Standen, Mary, additional, and Boudes, Pol, additional
- Published
- 2019
- Full Text
- View/download PDF
16. Emergent realities for social wellbeing : environmental, spatial and social pathways
- Author
-
Borg, Brian
- Subjects
Water utilities -- Malta ,Malta. Water Services Corporation ,Spatial analysis (Statistics) ,Geographic information systems -- Malta - Abstract
Making sure that water continues to flow irrespective of population growth, increases in tourism numbers and other seasonal demands, requires a large infrastructure, sophisticated technology, and a dedicated organisation behind it. The Water Services Corporation (WSC) in Malta has evolved over the past two decades into a modern corporation adopting innovative technological solutions and sophisticated technology that has helped deliver the best-quality service to customers. One way is by using geographic information system (GIS) based applications. Adopting this “spatial” strategy has enabled the WSC to determine how core business can exploit location data to improve decision-making, reduce risks, and optimise operations. The WSC is, as far as is known, the first large local organisation to adopt GIS to manage, control, and plan internal projects. Over the years the corporation has built up a very comprehensive GIS capacity that includes the geo-located points of all water meters, valves, taps, and pipes that exist on the Islands. Since the WSC is also responsible for Malta’s wastewater, the company also has the same facilities in this sector too, complete with slope angle and elevation data., peer-reviewed
- Published
- 2017
17. Sa1450 - Hepatoprotective Biomarkers, Amphiregulin and Soluble FAS, Increase During ELAD Treatment in Alcoholic Hepatitis Subjects
- Author
-
Lapetoda, Jason, primary, Anderson, Samantha, additional, Landeen, Lee K., additional, Al-Khafaji, Ali, additional, Parikh, Amay, additional, Duarte-Rojo, Andres, additional, Borg, Brian B., additional, McCaughan, Geoff, additional, Stein, Lance, additional, Allison, Michael, additional, Shah, Nikunj, additional, Subramanian, Ram, additional, Malik, Raza, additional, Brown, Robert S., additional, MacNicholas, Ross, additional, Asrani, Sumeet K., additional, Adhami, Talal, additional, Reich, David, additional, Thompson, Julie, additional, Chacko, Kristina, additional, Teperman, Lewis, additional, Hassanein, Tarek I., additional, and Bedard, Patty W., additional
- Published
- 2018
- Full Text
- View/download PDF
18. Sa1449 - Inflammation Biomarkers Decrease During ELAD Treatment in Alcoholic Hepatitis Subjects
- Author
-
Landeen, Lee K., primary, Lapetoda, Jason, additional, Bedard, Patty W., additional, Anderson, Samantha, additional, Li, Zheng, additional, Frank, William, additional, Al-Khafaji, Ali, additional, Parikh, Amay, additional, Duarte-Rojo, Andres, additional, Borg, Brian B., additional, McCaughan, Geoffrey W., additional, Stein, Lance, additional, Allison, Michael, additional, and Subramanian, Ram, additional
- Published
- 2018
- Full Text
- View/download PDF
19. Featured Cover.
- Author
-
Mayo, Marlyn J., Vierling, John M., Bowlus, Christopher L., Levy, Cynthia, Hirschfield, Gideon M., Neff, Guy W., Galambos, Michael R., Gordon, Stuart C., Borg, Brian B., Harrison, Stephen A., Thuluvath, Paul J., Goel, Aparna, Shiffman, Mitchell L., Swain, Mark G., Jones, David E. J., Trivedi, Palak, Kremer, Andreas E., Aspinall, Richard J., Sheridan, David A., and Dörffel, Yvonne
- Subjects
CHOLANGITIS ,CLINICAL trials ,PHARMACOLOGY - Abstract
This document is a featured cover image for the journal Alimentary Pharmacology & Therapeutics. The image is based on a clinical trial extension study on the safety and efficacy of seladelpar in patients with primary biliary cholangitis. The study was conducted by a team of authors and provides two-year results. The document does not provide any specific details or findings from the study, but it serves as a visual representation of the research. [Extracted from the article]
- Published
- 2024
- Full Text
- View/download PDF
20. Interleukin-6 (IL-6) haplotypes and the response to therapy of chronic hepatitis C virus infection
- Author
-
Yee, Leland J., Im, KyungAh, Borg, Brian, Yang, Huiying, and Liang, T. Jake
- Subjects
Adult ,Male ,Genotype ,Interleukin-6 ,Interferon-alpha ,Hepacivirus ,Hepatitis C, Chronic ,Interferon alpha-2 ,Middle Aged ,Polymorphism, Single Nucleotide ,Article ,Recombinant Proteins ,Polyethylene Glycols ,Cohort Studies ,Gene Expression Regulation ,Gene Frequency ,Haplotypes ,Multivariate Analysis ,Humans ,Female ,Alleles - Abstract
Chronic hepatitis C virus (HCV) infection affects nearly 170 million individuals worldwide. Treatment of HCV with pegylated interferon-alpha-2a is successful in eradicating virus from only 30 to 80% of those treated. Interleukin-6 (IL-6) is an important cytokine involved in the immune response to infectious agents and in vitro studies suggest that host genetic variation, particularly haplotypes, may affect IL-6 expression. We examined the contribution of haplotypes in the IL-6 gene on sustained viral response (SVR) to the therapy for chronic HCV infection. We observed the IL-6 T-T-G-G-G-G-C-A-G-A haplotype to be associated with a lower risk of achieving SVR among Caucasian Americans (CAs) ((relative risk) RR=0.80; 95% CI: 0.66-0.98; P=0.0261). Using a sliding window approach, the rs1800797-(G)-rs1800796-(G)-rs1800795-(G) haplotype was associated with a reduced chance of SVR (RR=0.79; 95% CI: 0.66-0.94; P=0.0081), as was the rs1800796-(G)-rs1800795-(G)-rs2069830-(C) haplotype (RR=0.78; 95% CI: 0.66-0.94; P=0.0065) among CAs. Overall, the rs1800797-(G)-rs1800796-(G)-rs1800795-(G) haplotype was independently associated with a reduced chance of SVR (RR=0.78; 95% CI: 0.62-1.0; P=0.0489) after adjustment for potential confounding factors. Our findings further illustrate the complexity of IL-6 genetic regulation and the potential importance of haplotypes on IL-6 expression. Our findings provide additional support for the potential importance of genetic variation in the IL-6 gene and the response to HCV therapy.
- Published
- 2009
21. A review of liver disorders in inflammatory bowel disease (IBD)
- Author
-
James Shah, Niraj, primary, K Gupta, Nitin, additional, and B Borg, Brian, additional
- Published
- 2017
- Full Text
- View/download PDF
22. Sa1020 Hepatitis B Virus Infection and Risk of Non-Hodgkin Lymphoma: A Meta-Analysis of Case-Control Studies
- Author
-
Kanth, Rajan, primary, Inaganti, Anupama, additional, Samji, Naga Swetha, additional, Komanapalli, Sarah D., additional, Borg, Brian B., additional, and Roy, Praveen K., additional
- Published
- 2013
- Full Text
- View/download PDF
23. Is Diabetes Mellitus a Risk Factor for Intrahepatic and Extrahepatic Cholangiocarcinoma?: A Meta-Analysis of Case Control Studies
- Author
-
Khan, Abdul S., primary, Tiwari, Priyanka, additional, Nass, Jonathan P., additional, Rihani, Tuhama, additional, Borg, Brian B., additional, Antillon, Mainor R., additional, and Roy, Praveen K., additional
- Published
- 2011
- Full Text
- View/download PDF
24. Chronic Hepatitis B and C Are Risk Factors for Intrahepatic Cholangiocarcinoma: A Meta-Analysis of Case Control Studies
- Author
-
Khan, Abdul S., primary, Tiwari, Priyanka, additional, Nass, Jonathan P., additional, Rihani, Tuhama, additional, Antillon, Mainor R., additional, Borg, Brian B., additional, and Roy, Praveen K., additional
- Published
- 2011
- Full Text
- View/download PDF
25. Autoantibodies to Extracellular Matrix Collagen: A Potential Novel Non-Invasive Biomarker of Fibrosis in Chronic Hepatitis C Infection
- Author
-
Seetharam, Anil B., primary, Subramanian, Vijay, additional, Borg, Brian B., additional, Ilias, Haseeb B., additional, Crippin, Jeffrey, additional, Chapman, William C., additional, and Mohanakumar, T., additional
- Published
- 2011
- Full Text
- View/download PDF
26. M1064 Queue Position in the Day's Endoscopic Schedule Impacts Effectiveness of Colonoscopy
- Author
-
Lee, Alexander, primary, Gupta, Nitin, additional, Iskander, John M., additional, Borg, Brian B., additional, Zuckerman, Gary R., additional, Banerjee, Bhaskar, additional, and Gyawali, C. Prakash, additional
- Published
- 2010
- Full Text
- View/download PDF
27. A functional SNP of interferon-γ gene is important for interferon-α-induced and spontaneous recovery from hepatitis C virus infection.
- Author
-
Ying Huang, Huiying Yang, Borg, Brian B., Xiaowen Su, Rhodes, Shannon L., Kai Yang, Xiaomei Tong, Tang, George, Howell, Charles D., Rosen, Hugo R., Thio, Chloe L., Thomas, David L., Alter, Harvey J., Sapp, Ronda K., and Liang, T. Jake
- Subjects
GENETIC polymorphisms ,INTERFERONS ,HEPATITIS C ,HEPATITIS C virus ,VIRAL hepatitis - Abstract
Cytokine polymorphisms are associated with disease outcome and interferon (IFN) treatment response in hepatitis C virus (HCV) infection. We genotyped eight SNPs spanning the entire IFN-γ gene in two cohorts and assessed the association between those polymorphisms and treatment response or spontaneous viral clearance. The first cohort was composed of 284 chronically HCV-infected patients who had received lFN-α-based therapy and the second was 251 i.v. drug users who had either spontaneously cleared HCV or become chronically infected. A SNP variant located in the proximal IFN-γ promoter region next to the binding motif of heat shock transcription factor (HSF), -764G. was significantly associated with sustained virological response [P = 0.04, odds ratio (OR) = 3.51 (confidence interval 1.0-12.5)]. The association was independently significant in multiple logistic regression (P = 0.04) along with race, viral titer, and genotype. This variant was also significantly associated with spontaneous recovery [P = 0.04, OR = 3.51 (1.0-12.5)] in the second cohort. Functional analyses show that the G allele confers a two- to three-fold higher promoter activity and stronger binding affinity to HSF1 than the C allele. Our study suggests that the IFN-γ promoter SNP-764G/C is functionally important in determining viral clearance and treatment response in HCV-infected patients and may be used as a genetic marker to predict sustained virological response in HCV-infected patients. [ABSTRACT FROM AUTHOR]
- Published
- 2007
- Full Text
- View/download PDF
28. Clinicopathological characteristics of TERT promoter mutation and telomere length in hepatocellular carcinoma
- Author
-
Lee, Hye Won, Park, Tae In, Jang, Se Young, Park, Soo Young, Park, Won-Jin, Jung, Soo-Jung, Lee, Jae-Ho, and Borg., Brian
- Published
- 2017
- Full Text
- View/download PDF
29. Four weeks of paritaprevir/ritonavir/ombitasvir plus dasabuvir encountering dengue fever resulted in sustained virological response in an HCV patient
- Author
-
Huang, Chung-Feng, Jang, Tyng-Yuan, Lu, Po-Liang, Yu, Ming-Lung, and Borg., Brian
- Published
- 2016
- Full Text
- View/download PDF
30. Computed Tomography-Guided Radiofrequency Ablation Following Transcatheter Arterial Embolization in Treatment of Large Hepatic Hemangiomas
- Author
-
Ji, Jiansong, Gao, Jun, Zhao, Lizhen, Tu, Jianfei, Song, Jingjing, Sun, Wenbing, and Borg., Brian
- Published
- 2016
- Full Text
- View/download PDF
31. Obeticholic acid for the treatment of non-alcoholic steatohepatitis: interim analysis from a multicentre, randomised, placebo-controlled phase 3 trial
- Author
-
Zobair M Younossi, Vlad Ratziu, Rohit Loomba, Mary Rinella, Quentin M Anstee, Zachary Goodman, Pierre Bedossa, Andreas Geier, Susanne Beckebaum, Philip N Newsome, David Sheridan, Muhammad Y Sheikh, James Trotter, Whitfield Knapple, Eric Lawitz, Manal F Abdelmalek, Kris V Kowdley, Aldo J Montano-Loza, Jerome Boursier, Philippe Mathurin, Elisabetta Bugianesi, Giuseppe Mazzella, Antonio Olveira, Helena Cortez-Pinto, Isabel Graupera, David Orr, Lise Lotte Gluud, Jean-Francois Dufour, David Shapiro, Jason Campagna, Luna Zaru, Leigh MacConell, Reshma Shringarpure, Stephen Harrison, Arun J Sanyal, Manal Abdelmalek, Gary Abrams, Humberto Aguilar, Aijaz Ahmed, Elmar Aigner, Guruprasad Aithal, Aftab Ala, William Alazawi, Agustin Albillos, Michael Allison, Sfa Al-Shamma, Raul Andrade, Pietro Andreone, Mario Angelico, Victor Ankoma-Sey, Quentin Anstee, Rodolphe Anty, Victor Araya, Juan Ignacio Arenas Ruiz, Perttu Arkkila, Marty Arora, Tarik Asselah, Jennifer Au, Oyekoya Ayonrinde, Robert James Bailey, Maya Balakrishnan, Kiran Bambha, Meena Bansal, Sidney Barritt, John Bate, Jorge Beato, Jaideep Behari, Pablo Bellot, Ziv Ben Ari, Michael Bennett, Marina Berenguer, Benedetta Terziroli Beretta-Piccoli, Thomas Berg, Maurizio Bonacini, Lucia Bonet, Brian Borg, Marc Bourliere, William Bowman, David Bradley, Marija Brankovic, Marius Braun, Jean-Pierre Bronowicki, Savino Bruno, Cindy Cai, Amy Calderon, José Luis Calleja Panero, Elizabeth Carey, Michal Carmiel, Jose Antonio Carrión, Matthew Cave, Cristina Chagas, Tawfik Chami, Alan Chang, Allan Coates, Jeremy Cobbold, Charlote Costentin, Kathleen Corey, Lynsey Corless, Javier Crespo, Oscar Cruz Pereira, Victor de Ledinghen, Andrew deLemos, Moises Diago, Mamie Dong, Jean-François Dufour, Predrag Dugalic, Winston Dunn, Magby Elkhashab, Michael Epstein, Maria Desamparados Escudero-Garcia, Ohad Etzion, Larry Evans, Robert Falcone, Conrado Fernandez, Jose Ferreira, Scott Fink, Kevin Finnegan, Roberto Firpi-Morell, Annarosa Floreani, Thierry Fontanges, Ryan Ford, Ewan Forrest, Andrew Fowell, Anna Ludovica Fracanzani, Sven Francque, Bradley Freilich, Juan Frias, Michael Fuchs, Javier Fuentes, Michael Galambos, Juan Gallegos, Anja Geerts, Jacob George, Maged Ghali, Reem Ghalib, Pierre Gholam, Pere Gines, Norman Gitlin, Tobias Goeser, John Goff, Stuart Gordon, Frederic Gordon, Odile Goria, Shaun Greer, Alla Grigorian, Henning Gronbaek, Maeva Guillaume, Naresh Gunaratnam, Dina Halegoua-De Marzio, Bilal Hameed, Stephanie Hametner, James Hamilton, Marek Hartleb, Tarek Hassanein, Dieter Häussinger, Paul Hellstern, Robert Herring, Eva Heurich, Christophe Hezode, Holger Hinrichsen, Peter Holland Fischer, Yves Horsmans, Jonathan Huang, Hyder Hussaini, Antoine Jakiche, Lennox Jeffers, Blake Jones, Rosa Jorge, Francisco Jorquera, Shoba Joshi, Alisan Kahraman, Kelly Kaita, Nicholas Karyotakis, Zeid Kayali, Stergios Kechagias, Thomas Kepczyk, Mandana Khalili, Hicham Khallafi, Johannes Kluwe, Anita Kohli, Kevin Korenblat, Kris Kowdley, Aleksander Krag, Richard Krause, Andreas Kremer, Karen Krok, Miodrag Krstic, Marcelo Kugelmas, Sonal Kumar, Scott Kuwada, Damien Labarriere, Michelle Lai, Wim Laleman, Pietro Lampertico, Alice Lee, Vincent Leroy, Steven Lidofsky, Tina Huey Lim, Joseph Lim, Donald Lipkis, Ester Little, Amadeo Lonardo, Michelle Long, Velimir Anthony Christopher Luketic, Yoav Lurie, Guilherme Macedo, Joana Magalhaes, Mihály Makara, Benedict Maliakkal, Michael Manns, Pinelopi Manousou, Parvez Mantry, Giulio Marchesini, Carla Marinho, Paul Marotta, Hanns-Ulrich Marschall, Linda Martinez, Marlyn Mayo, Mark McCullen, William McLaughlin, Uta Merle, Raphael Merriman, Apurva Modi, Esther Molina, Aldo Montano-Loza, Carlos Monteverde, Amilcar Morales Cardona, Sulleman Moreea, Christophe Moreno, Filomena Morisco, Abdullah Mubarak, Beat Muellhaupt, Sandeep Mukherjee, Tobias Müller, Aleksandar Nagorni, Jahnavi Naik, Guy Neff, Moises Nevah, Philip Newsome, Eric Nguyen-Khac, Mazen Noureddin, Jude Oben, Hans Orlent, James Orr, Grisell Ortiz-Lasanta, Violaine Ozenne, Prashant Pandya, Angelo Paredes, James Park, Joykumar Patel, Keyur Patel, Sonali Paul, Heather Patton, Markus Peck-Radosavljevic, Salvatore Petta, Stephen Pianko, Anna Piekarska, Neville Pimstone, Joseph Pisegna, Paul Pockros, Stanislas Pol, Michael Porayko, John Poulos, David Pound, Joe Pouzar, Jose Presa Ramos, Nikolaos Pyrsopoulos, Nila Rafiq, Kate Muller, Alnoor Ramji, Ravi Ravinuthala, Chakradhar Reddy, Gautham Reddy K G, K. Rajender Reddy K R, Frederic Regenstein, Robert Reindollar, Justin Reynolds, Andres Riera, Jose Rivera Acosta, Geert Robaeys, Stuart Roberts, Federico Rodriguez-Perez, Sandor Romero, Manuel Romero-Gomez, Raymond Rubin, Mariagrazia Rumi, Simon Rushbrook, Christian Rust, Michael Ryan, Rifaat Safadi, Adnan Said, Kimmo Salminen, Didier Samuel, John Santoro, Arun Sanyal, Souvik Sarkar, Cynthia Schaeffer, Jörn Schattenberg, Ingolf Schiefke, Eugene Schiff, Wolfgang Schmidt, Jeffrey Schneider, Jeoffrey Schouten, Michael Schultz, Giada Sebastiani, David Semela, Thomas Sepe, Aasim Sheikh, Muhammad Sheikh, Kenneth Sherman, Oren Shibolet, Mitchell Shiffman, Asma Siddique, Cyril Sieberhagen, Samuel Sigal, Katarzyna Sikorska, Krzysztof Simon, Marie Sinclair, Richard Skoien, Joel Solis, Siddharth Sood, Bob Souder, James Spivey, Per Stal, Laura Stinton, Simone Strasser, Petar Svorcan, Gyongzi Szabo, Andrew Talal, Edward Tam, Brent Tetri, Paul Thuluvath, Hillel Tobias, Krzysztof Tomasiewicz, Dawn Torres, Albert Tran, Michael Trauner, Christian Trautwein, Emanuel Tsochatzis, Esther Unitt, Victor Vargas, Istvan Varkonyi, Ella Veitsman, Umberto Vespasiani Gentilucci, David Victor, John Vierling, Catherine Vincent, Aron Vincze, Manfred von der Ohe, Natasha Von Roenn, Raj Vuppalanchi, Michael Waters, Kymberly Watt, Julia Wattacheril, Martin Weltman, Amanda Wieland, Gregory Wiener, Alonzo Williams A, Jeffrey Williams J, Jason Wilson, Maria Yataco, Eric Yoshida, Ziad Younes, Liyun Yuan, Adam Zivony, Donald Zogg, Heinz Zoller, Fabien Zoulim, Eli Zuckerman, Massimo Zuin, Younossi Z.M., Ratziu V., Loomba R., Rinella M., Anstee Q.M., Goodman Z., Bedossa P., Geier A., Beckebaum S., Newsome P.N., Sheridan D., Sheikh M.Y., Trotter J., Knapple W., Lawitz E., Abdelmalek M.F., Kowdley K.V., Montano-Loza A.J., Boursier J., Mathurin P., Bugianesi E., Mazzella G., Olveira A., Cortez-Pinto H., Graupera I., Orr D., Gluud L.L., Dufour J.-F., Shapiro D., Campagna J., Zaru L., MacConell L., Shringarpure R., Harrison S., Sanyal A.J., Abdelmalek M., Abrams G., Aguilar H., Ahmed A., Aigner E., Aithal G., Ala A., Alazawi W., Albillos A., Allison M., Al-Shamma S., Andrade R., Andreone P., Angelico M., Ankoma-Sey V., Anstee Q., Anty R., Araya V., Arenas Ruiz J.I., Arkkila P., Arora M., Asselah T., Au J., Ayonrinde O., Bailey R.J., Balakrishnan M., Bambha K., Bansal M., Barritt S., Bate J., Beato J., Behari J., Bellot P., Ben Ari Z., Bennett M., Berenguer M., Beretta-Piccoli B.T., Berg T., Bonacini M., Bonet L., Borg B., Bourliere M., Bowman W., Bradley D., Brankovic M., Braun M., Bronowicki J.-P., Bruno S., Cai C., Calleja Panero J.L., Carey E., Carmiel M., Carrion J.A., Cave M., Chagas C., Chami T., Chang A., Coates A., Cobbold J., Corey K., Corless L., Crespo J., Cruz Pereira O., de Ledinghen V., deLemos A., Diago M., Dugalic P., Dunn W., Elkhashab M., Epstein M., Escudero-Garcia M.D., Etzion O., Evans L., Falcone R., Fernandez C., Ferreira J., Fink S., Finnegan K., Firpi-Morell R., Floreani A., Fontanges T., Ford R., Forrest E., Fowell A., Fracanzani A.L., Francque S., Freilich B., Frias J., Fuchs M., Fuentes J., Galambos M., Gallegos J., Geerts A., George J., Ghali M., Ghalib R., Gholam P., Gines P., Gitlin N., Goeser T., Goff J., Gordon S., Gordon F., Goria O., Greer S., Grigorian A., Gronbaek H., Guillaume M., Gunaratnam N., Halegoua-De Marzio D., Hameed B., Hametner S., Hamilton J., Hartleb M., Hassanein T., Haussinger D., Hellstern P., Herring R., Heurich E., Hezode C., Hinrichsen H., Holland Fischer P., Horsmans Y., Huang J., Jakiche A., Jeffers L., Jones B., Jorge R., Jorquera F., Kahraman A., Kaita K., Karyotakis N., Kayali Z., Kechagias S., Kepczyk T., Khalili M., Khallafi H., Kluwe J., Kohli A., Korenblat K., Kowdley K., Krag A., Krause R., Kremer A., Krok K., Krstic M., Kugelmas M., Kumar S., Labarriere D., Lai M., Lampertico P., Lee A., Leroy V., Lidofsky S., Lim T.H., Lim J., Lipkis D., Little E., Lonardo A., Long M., Lurie Y., Macedo G., Makara M., Maliakkal B., Manns M., Manousou P., Mantry P., Marchesini G., Marinho C., Marotta P., Marschall H.-U., Mayo M., McCullen M., McLaughlin W., Merriman R., Modi A., Molina E., Montano-Loza A., Monteverde C., Moreea S., Moreno C., Morisco F., Mubarak A., Muellhaupt B., Mukherjee S., Muller T., Nagorni A., Naik J., Neff G., Nevah M., Newsome P., Nguyen-Khac E., Noureddin M., Oben J., Orlent H., Orr J., Ortiz-Lasanta G., Ozenne V., Pandya P., Paredes A., Park J., Patel J., Patel K., Uta M., Patton H., Peck-Radosavljevic M., Petta S., Pianko S., Piekarska A., Pimstone N., Pockros P., Pol S., Porayko M., Poulos J., Pound D., Pouzar J., Presa Ramos J., Pyrsopoulos N., Rafiq N., Muller K., Ramji A., Ravinuthala R., Reddy C., Reddy K G G., Reddy K R K.R., Regenstein F., Reindollar R., Riera A., Rivera Acosta J., Robaeys G., Roberts S., Rodriguez-Perez F., Romero-Gomez M., Rubin R., Rumi M., Rushbrook S., Rust C., Ryan M., Safadi R., Said A., Salminen K., Samuel D., Santoro J., Sanyal A., Sarkar S., Schaeffer C., Schattenberg J., Schiefke I., Schiff E., Schmidt W., Schneider J., Schouten J., Schultz M., Sebastiani G., Semela D., Sepe T., Sheikh A., Sheikh M., Sherman K., Shibolet O., Shiffman M., Siddique A., Sieberhagen C., Sigal S., Sikorska K., Simon K., Sinclair M., Skoien R., Solis J., Sood S., Souder B., Spivey J., Stal P., Stinton L., Strasser S., Svorcan P., Szabo G., Talal A., Tam E., Tetri B., Thuluvath P., Tobias H., Tomasiewicz K., Torres D., Trauner M., Trautwein C., Tsochatzis E., Unitt E., Vargas V., Varkonyi I., Veitsman E., Vespasiani Gentilucci U., Victor D., Vierling J., Vincent C., Vincze A., von der Ohe M., Von Roenn N., Vuppalanchi R., Waters M., Watt K., Weltman M., Wieland A., Wiener G., Williams A A., Williams J J., Wilson J., Yataco M., Yoshida E., Younes Z., Yuan L., Zivony A., Zogg D., Zoller H., Zoulim F., Zuckerman E., Zuin M., Repositório da Universidade de Lisboa, Younossi, Z. M., Ratziu, V., Loomba, R., Rinella, M., Anstee, Q. M., Goodman, Z., Bedossa, P., Geier, A., Beckebaum, S., Newsome, P. N., Sheridan, D., Sheikh, M. Y., Trotter, J., Knapple, W., Lawitz, E., Abdelmalek, M. F., Kowdley, K. V., Montano-Loza, A. J., Boursier, J., Mathurin, P., Bugianesi, E., Mazzella, G., Olveira, A., Cortez-Pinto, H., Graupera, I., Orr, D., Gluud, L. L., Dufour, J. -F., Shapiro, D., Campagna, J., Zaru, L., Macconell, L., Shringarpure, R., Harrison, S., Sanyal, A. J., Abdelmalek, M., Abrams, G., Aguilar, H., Ahmed, A., Aigner, E., Aithal, G., Ala, A., Alazawi, W., Albillos, A., Allison, M., Al-Shamma, S., Andrade, R., Andreone, P., Angelico, M., Ankoma-Sey, V., Anstee, Q., Anty, R., Araya, V., Arenas Ruiz, J. I., Arkkila, P., Arora, M., Asselah, T., Au, J., Ayonrinde, O., Bailey, R. J., Balakrishnan, M., Bambha, K., Bansal, M., Barritt, S., Bate, J., Beato, J., Behari, J., Bellot, P., Ben Ari, Z., Bennett, M., Berenguer, M., Beretta-Piccoli, B. T., Berg, T., Bonacini, M., Bonet, L., Borg, B., Bourliere, M., Bowman, W., Bradley, D., Brankovic, M., Braun, M., Bronowicki, J. -P., Bruno, S., Cai, C., Calleja Panero, J. L., Carey, E., Carmiel, M., Carrion, J. A., Cave, M., Chagas, C., Chami, T., Chang, A., Coates, A., Cobbold, J., Corey, K., Corless, L., Crespo, J., Cruz Pereira, O., de Ledinghen, V., Delemos, A., Diago, M., Dugalic, P., Dunn, W., Elkhashab, M., Epstein, M., Escudero-Garcia, M. D., Etzion, O., Evans, L., Falcone, R., Fernandez, C., Ferreira, J., Fink, S., Finnegan, K., Firpi-Morell, R., Floreani, A., Fontanges, T., Ford, R., Forrest, E., Fowell, A., Fracanzani, A. L., Francque, S., Freilich, B., Frias, J., Fuchs, M., Fuentes, J., Galambos, M., Gallegos, J., Geerts, A., George, J., Ghali, M., Ghalib, R., Gholam, P., Gines, P., Gitlin, N., Goeser, T., Goff, J., Gordon, S., Gordon, F., Goria, O., Greer, S., Grigorian, A., Gronbaek, H., Guillaume, M., Gunaratnam, N., Halegoua-De Marzio, D., Hameed, B., Hametner, S., Hamilton, J., Hartleb, M., Hassanein, T., Haussinger, D., Hellstern, P., Herring, R., Heurich, E., Hezode, C., Hinrichsen, H., Holland Fischer, P., Horsmans, Y., Huang, J., Jakiche, A., Jeffers, L., Jones, B., Jorge, R., Jorquera, F., Kahraman, A., Kaita, K., Karyotakis, N., Kayali, Z., Kechagias, S., Kepczyk, T., Khalili, M., Khallafi, H., Kluwe, J., Kohli, A., Korenblat, K., Kowdley, K., Krag, A., Krause, R., Kremer, A., Krok, K., Krstic, M., Kugelmas, M., Kumar, S., Labarriere, D., Lai, M., Lampertico, P., Lee, A., Leroy, V., Lidofsky, S., Lim, T. H., Lim, J., Lipkis, D., Little, E., Lonardo, A., Long, M., Lurie, Y., Macedo, G., Makara, M., Maliakkal, B., Manns, M., Manousou, P., Mantry, P., Marchesini, G., Marinho, C., Marotta, P., Marschall, H. -U., Mayo, M., Mccullen, M., Mclaughlin, W., Merriman, R., Modi, A., Molina, E., Montano-Loza, A., Monteverde, C., Moreea, S., Moreno, C., Morisco, F., Mubarak, A., Muellhaupt, B., Mukherjee, S., Muller, T., Nagorni, A., Naik, J., Neff, G., Nevah, M., Newsome, P., Nguyen-Khac, E., Noureddin, M., Oben, J., Orlent, H., Orr, J., Ortiz-Lasanta, G., Ozenne, V., Pandya, P., Paredes, A., Park, J., Patel, J., Patel, K., Uta, M., Patton, H., Peck-Radosavljevic, M., Petta, S., Pianko, S., Piekarska, A., Pimstone, N., Pockros, P., Pol, S., Porayko, M., Poulos, J., Pound, D., Pouzar, J., Presa Ramos, J., Pyrsopoulos, N., Rafiq, N., Muller, K., Ramji, A., Ravinuthala, R., Reddy, C., Reddy K G, G., Reddy K R, K. R., Regenstein, F., Reindollar, R., Riera, A., Rivera Acosta, J., Robaeys, G., Roberts, S., Rodriguez-Perez, F., Romero-Gomez, M., Rubin, R., Rumi, M., Rushbrook, S., Rust, C., Ryan, M., Safadi, R., Said, A., Salminen, K., Samuel, D., Santoro, J., Sanyal, A., Sarkar, S., Schaeffer, C., Schattenberg, J., Schiefke, I., Schiff, E., Schmidt, W., Schneider, J., Schouten, J., Schultz, M., Sebastiani, G., Semela, D., Sepe, T., Sheikh, A., Sheikh, M., Sherman, K., Shibolet, O., Shiffman, M., Siddique, A., Sieberhagen, C., Sigal, S., Sikorska, K., Simon, K., Sinclair, M., Skoien, R., Solis, J., Sood, S., Souder, B., Spivey, J., Stal, P., Stinton, L., Strasser, S., Svorcan, P., Szabo, G., Talal, A., Tam, E., Tetri, B., Thuluvath, P., Tobias, H., Tomasiewicz, K., Torres, D., Trauner, M., Trautwein, C., Tsochatzis, E., Unitt, E., Vargas, V., Varkonyi, I., Veitsman, E., Vespasiani Gentilucci, U., Victor, D., Vierling, J., Vincent, C., Vincze, A., von der Ohe, M., Von Roenn, N., Vuppalanchi, R., Waters, M., Watt, K., Weltman, M., Wieland, A., Wiener, G., Williams A, A., Williams J, J., Wilson, J., Yataco, M., Yoshida, E., Younes, Z., Yuan, L., Zivony, A., Zogg, D., Zoller, H., Zoulim, F., Zuckerman, E., Zuin, M., Younossi, Zobair M, Ratziu, Vlad, Loomba, Rohit, Rinella, Mary, Anstee, Quentin M, Goodman, Zachary, Bedossa, Pierre, Geier, Andrea, Beckebaum, Susanne, Newsome, Philip N, Sheridan, David, Sheikh, Muhammad Y, Trotter, Jame, Knapple, Whitfield, Lawitz, Eric, Abdelmalek, Manal F, Kowdley, Kris V, Montano-Loza, Aldo J, Boursier, Jerome, Mathurin, Philippe, Bugianesi, Elisabetta, Mazzella, Giuseppe, Olveira, Antonio, Cortez-Pinto, Helena, Graupera, Isabel, Orr, David, Gluud, Lise Lotte, Dufour, Jean-Francoi, Shapiro, David, Campagna, Jason, Zaru, Luna, MacConell, Leigh, Shringarpure, Reshma, Harrison, Stephen, Sanyal, Arun J, Abdelmalek, Manal, Abrams, Gary, Aguilar, Humberto, Ahmed, Aijaz, Aigner, Elmar, Aithal, Guruprasad, Ala, Aftab, Alazawi, William, Albillos, Agustin, Allison, Michael, Al-Shamma, Sfa, Andrade, Raul, Andreone, Pietro, Angelico, Mario, Ankoma-Sey, Victor, Anstee, Quentin, Anty, Rodolphe, Araya, Victor, Arenas Ruiz, Juan Ignacio, Arkkila, Perttu, Arora, Marty, Asselah, Tarik, Au, Jennifer, Ayonrinde, Oyekoya, Bailey, Robert Jame, Balakrishnan, Maya, Bambha, Kiran, Bansal, Meena, Barritt, Sidney, Bate, John, Beato, Jorge, Behari, Jaideep, Bellot, Pablo, Ben Ari, Ziv, Bennett, Michael, Berenguer, Marina, Beretta-Piccoli, Benedetta Terziroli, Berg, Thoma, Bonacini, Maurizio, Bonet, Lucia, Borg, Brian, Bourliere, Marc, Bowman, William, Bradley, David, Brankovic, Marija, Braun, Mariu, Bronowicki, Jean-Pierre, Bruno, Savino, Cai, Cindy, Calleja Panero, José Lui, Carey, Elizabeth, Carmiel, Michal, Carrión, Jose Antonio, Cave, Matthew, Chagas, Cristina, Chami, Tawfik, Chang, Alan, Coates, Allan, Cobbold, Jeremy, Corey, Kathleen, Corless, Lynsey, Crespo, Javier, Cruz Pereira, Oscar, de Ledinghen, Victor, deLemos, Andrew, Diago, Moise, Dufour, Jean-Françoi, Dugalic, Predrag, Dunn, Winston, Elkhashab, Magby, Epstein, Michael, Escudero-Garcia, Maria Desamparado, Etzion, Ohad, Evans, Larry, Falcone, Robert, Fernandez, Conrado, Ferreira, Jose, Fink, Scott, Finnegan, Kevin, Firpi-Morell, Roberto, Floreani, Annarosa, Fontanges, Thierry, Ford, Ryan, Forrest, Ewan, Fowell, Andrew, Fracanzani, Anna Ludovica, Francque, Sven, Freilich, Bradley, Frias, Juan, Fuchs, Michael, Fuentes, Javier, Galambos, Michael, Gallegos, Juan, Geerts, Anja, George, Jacob, Ghali, Maged, Ghalib, Reem, Gholam, Pierre, Gines, Pere, Gitlin, Norman, Goeser, Tobia, Goff, John, Gordon, Stuart, Gordon, Frederic, Goria, Odile, Greer, Shaun, Grigorian, Alla, Gronbaek, Henning, Guillaume, Maeva, Gunaratnam, Naresh, Halegoua-De Marzio, Dina, Hameed, Bilal, Hametner, Stephanie, Hamilton, Jame, Hartleb, Marek, Hassanein, Tarek, Häussinger, Dieter, Hellstern, Paul, Herring, Robert, Heurich, Eva, Hezode, Christophe, Hinrichsen, Holger, Holland Fischer, Peter, Horsmans, Yve, Huang, Jonathan, Jakiche, Antoine, Jeffers, Lennox, Jones, Blake, Jorge, Rosa, Jorquera, Francisco, Kahraman, Alisan, Kaita, Kelly, Karyotakis, Nichola, Kayali, Zeid, Kechagias, Stergio, Kepczyk, Thoma, Khalili, Mandana, Khallafi, Hicham, Kluwe, Johanne, Kohli, Anita, Korenblat, Kevin, Kowdley, Kri, Krag, Aleksander, Krause, Richard, Kremer, Andrea, Krok, Karen, Krstic, Miodrag, Kugelmas, Marcelo, Kumar, Sonal, Labarriere, Damien, Lai, Michelle, Lampertico, Pietro, Lee, Alice, Leroy, Vincent, Lidofsky, Steven, Lim, Tina Huey, Lim, Joseph, Lipkis, Donald, Little, Ester, Lonardo, Amadeo, Long, Michelle, Lurie, Yoav, Macedo, Guilherme, Makara, Mihály, Maliakkal, Benedict, Manns, Michael, Manousou, Pinelopi, Mantry, Parvez, Marchesini, Giulio, Marinho, Carla, Marotta, Paul, Marschall, Hanns-Ulrich, Mayo, Marlyn, McCullen, Mark, McLaughlin, William, Merriman, Raphael, Modi, Apurva, Molina, Esther, Montano-Loza, Aldo, Monteverde, Carlo, Moreea, Sulleman, Moreno, Christophe, Morisco, Filomena, Mubarak, Abdullah, Muellhaupt, Beat, Mukherjee, Sandeep, Müller, Tobia, Nagorni, Aleksandar, Naik, Jahnavi, Neff, Guy, Nevah, Moise, Newsome, Philip, Nguyen-Khac, Eric, Noureddin, Mazen, Oben, Jude, Orlent, Han, Orr, Jame, Ortiz-Lasanta, Grisell, Ozenne, Violaine, Pandya, Prashant, Paredes, Angelo, Park, Jame, Patel, Joykumar, Patel, Keyur, Uta, Merle, Patton, Heather, Peck-Radosavljevic, Marku, Petta, Salvatore, Pianko, Stephen, Piekarska, Anna, Pimstone, Neville, Pockros, Paul, Pol, Stanisla, Porayko, Michael, Poulos, John, Pound, David, Pouzar, Joe, Presa Ramos, Jose, Pyrsopoulos, Nikolao, Rafiq, Nila, Muller, Kate, Ramji, Alnoor, Ravinuthala, Ravi, Reddy, Chakradhar, Reddy K G, Gautham, Reddy K R, K. Rajender, Regenstein, Frederic, Reindollar, Robert, Riera, Andre, Rivera Acosta, Jose, Robaeys, Geert, Roberts, Stuart, Rodriguez-Perez, Federico, Romero-Gomez, Manuel, Rubin, Raymond, Rumi, Mariagrazia, Rushbrook, Simon, Rust, Christian, Ryan, Michael, Safadi, Rifaat, Said, Adnan, Salminen, Kimmo, Samuel, Didier, Santoro, John, Sanyal, Arun, Sarkar, Souvik, Schaeffer, Cynthia, Schattenberg, Jörn, Schiefke, Ingolf, Schiff, Eugene, Schmidt, Wolfgang, Schneider, Jeffrey, Schouten, Jeoffrey, Schultz, Michael, Sebastiani, Giada, Semela, David, Sepe, Thoma, Sheikh, Aasim, Sheikh, Muhammad, Sherman, Kenneth, Shibolet, Oren, Shiffman, Mitchell, Siddique, Asma, Sieberhagen, Cyril, Sigal, Samuel, Sikorska, Katarzyna, Simon, Krzysztof, Sinclair, Marie, Skoien, Richard, Solis, Joel, Sood, Siddharth, Souder, Bob, Spivey, Jame, Stal, Per, Stinton, Laura, Strasser, Simone, Svorcan, Petar, Szabo, Gyongzi, Talal, Andrew, Tam, Edward, Tetri, Brent, Thuluvath, Paul, Tobias, Hillel, Tomasiewicz, Krzysztof, Torres, Dawn, Trauner, Michael, Trautwein, Christian, Tsochatzis, Emanuel, Unitt, Esther, Vargas, Victor, Varkonyi, Istvan, Veitsman, Ella, Vespasiani Gentilucci, Umberto, Victor, David, Vierling, John, Vincent, Catherine, Vincze, Aron, von der Ohe, Manfred, Von Roenn, Natasha, Vuppalanchi, Raj, Waters, Michael, Watt, Kymberly, Weltman, Martin, Wieland, Amanda, Wiener, Gregory, Williams A, Alonzo, Williams J, Jeffrey, Wilson, Jason, Yataco, Maria, Yoshida, Eric, Younes, Ziad, Yuan, Liyun, Zivony, Adam, Zogg, Donald, Zoller, Heinz, Zoulim, Fabien, Zuckerman, Eli, Zuin, Massimo, and REGENERATE Study Investigators
- Subjects
Male ,Biopsy ,Clinical Trial, Phase III ,Administration, Oral ,030204 cardiovascular system & hematology ,Chronic liver disease ,Settore MED/04 ,Biomarkers/analysis ,Gastroenterology ,chemistry.chemical_compound ,0302 clinical medicine ,Liver Function Tests ,Non-alcoholic Fatty Liver Disease ,Clinical endpoint ,Medicine ,030212 general & internal medicine ,610 Medicine & health ,Chenodeoxycholic Acid/administration & dosage ,education.field_of_study ,Liver Function Test ,Research Support, Non-U.S. Gov't ,Fatty liver ,Obeticholic acid ,NASH, OBETICHOLIC ACID ,General Medicine ,Middle Aged ,Multicenter Study ,Randomized Controlled Trial ,Administration ,Female ,Biomarkers ,Chenodeoxycholic Acid ,Double-Blind Method ,Humans ,Human ,Oral ,medicine.medical_specialty ,Population ,Placebo ,03 medical and health sciences ,Research Support, N.I.H., Extramural ,Internal medicine ,Journal Article ,education ,Intention-to-treat analysis ,business.industry ,Biomarker ,Interim analysis ,medicine.disease ,Non-alcoholic Fatty Liver Disease/drug therapy ,chemistry ,Human medicine ,business - Abstract
© 2019 Elsevier Ltd. All rights reserved., Background: Non-alcoholic steatohepatitis (NASH) is a common type of chronic liver disease that can lead to cirrhosis. Obeticholic acid, a farnesoid X receptor agonist, has been shown to improve the histological features of NASH. Here we report results from a planned interim analysis of an ongoing, phase 3 study of obeticholic acid for NASH. Methods: In this multicentre, randomised, double-blind, placebo-controlled study, adult patients with definite NASH, non-alcoholic fatty liver disease (NAFLD) activity score of at least 4, and fibrosis stages F2-F3, or F1 with at least one accompanying comorbidity, were randomly assigned using an interactive web response system in a 1:1:1 ratio to receive oral placebo, obeticholic acid 10 mg, or obeticholic acid 25 mg daily. Patients were excluded if cirrhosis, other chronic liver disease, elevated alcohol consumption, or confounding conditions were present. The primary endpoints for the month-18 interim analysis were fibrosis improvement (≥1 stage) with no worsening of NASH, or NASH resolution with no worsening of fibrosis, with the study considered successful if either primary endpoint was met. Primary analyses were done by intention to treat, in patients with fibrosis stage F2-F3 who received at least one dose of treatment and reached, or would have reached, the month 18 visit by the prespecified interim analysis cutoff date. The study also evaluated other histological and biochemical markers of NASH and fibrosis, and safety. This study is ongoing, and registered with ClinicalTrials.gov, NCT02548351, and EudraCT, 20150-025601-6. Findings: Between Dec 9, 2015, and Oct 26, 2018, 1968 patients with stage F1-F3 fibrosis were enrolled and received at least one dose of study treatment; 931 patients with stage F2-F3 fibrosis were included in the primary analysis (311 in the placebo group, 312 in the obeticholic acid 10 mg group, and 308 in the obeticholic acid 25 mg group). The fibrosis improvement endpoint was achieved by 37 (12%) patients in the placebo group, 55 (18%) in the obeticholic acid 10 mg group (p=0·045), and 71 (23%) in the obeticholic acid 25 mg group (p=0·0002). The NASH resolution endpoint was not met (25 [8%] patients in the placebo group, 35 [11%] in the obeticholic acid 10 mg group [p=0·18], and 36 [12%] in the obeticholic acid 25 mg group [p=0·13]). In the safety population (1968 patients with fibrosis stages F1-F3), the most common adverse event was pruritus (123 [19%] in the placebo group, 183 [28%] in the obeticholic acid 10 mg group, and 336 [51%] in the obeticholic acid 25 mg group); incidence was generally mild to moderate in severity. The overall safety profile was similar to that in previous studies, and incidence of serious adverse events was similar across treatment groups (75 [11%] patients in the placebo group, 72 [11%] in the obeticholic acid 10 mg group, and 93 [14%] in the obeticholic acid 25 mg group). Interpretation: Obeticholic acid 25 mg significantly improved fibrosis and key components of NASH disease activity among patients with NASH. The results from this planned interim analysis show clinically significant histological improvement that is reasonably likely to predict clinical benefit. This study is ongoing to assess clinical outcomes.
- Published
- 2019
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.